Denali Therapeutics Inc (NASDAQ:DNLI) has been given an average broker rating score of 1.17 (Strong Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company.

Analysts have set a 1 year consensus price objective of $24.67 for the company and are anticipating that the company will post ($0.30) earnings per share for the current quarter, according to Zacks. Zacks has also given Denali Therapeutics an industry rank of 184 out of 265 based on the ratings given to related companies.

Several equities research analysts have recently commented on DNLI shares. Goldman Sachs Group started coverage on Denali Therapeutics in a research note on Tuesday, January 2nd. They set a “neutral” rating on the stock. Evercore ISI started coverage on Denali Therapeutics in a research note on Tuesday, January 2nd. They set an “outperform” rating and a $23.00 price target on the stock. Morgan Stanley started coverage on Denali Therapeutics in a research note on Tuesday, January 2nd. They set an “overweight” rating and a $25.00 price target on the stock. Finally, JPMorgan Chase & Co. started coverage on Denali Therapeutics in a research note on Tuesday, January 2nd. They set an “overweight” rating and a $24.00 price target on the stock.

In related news, major shareholder Douglas K. Bratton bought 275,000 shares of Denali Therapeutics stock in a transaction that occurred on Tuesday, December 12th. The shares were purchased at an average price of $18.00 per share, with a total value of $4,950,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

A number of hedge funds have recently bought and sold shares of DNLI. Landscape Capital Management L.L.C. purchased a new stake in Denali Therapeutics in the 4th quarter valued at approximately $166,000. MYDA Advisors LLC purchased a new stake in Denali Therapeutics in the 4th quarter valued at approximately $188,000. Gilder Gagnon Howe & Co. LLC purchased a new stake in Denali Therapeutics in the 4th quarter valued at approximately $237,000. Wolverine Asset Management LLC purchased a new stake in Denali Therapeutics in the 4th quarter valued at approximately $249,000. Finally, Wells Fargo & Company MN purchased a new stake in Denali Therapeutics in the 4th quarter valued at approximately $621,000. 23.56% of the stock is currently owned by hedge funds and other institutional investors.

Denali Therapeutics (NASDAQ DNLI) traded up $1.46 during midday trading on Monday, reaching $24.80. Denali Therapeutics has a one year low of $14.72 and a one year high of $25.02. The firm has a market cap of $2,180.00 and a price-to-earnings ratio of -24.08.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/19/1157183.html.

Denali Therapeutics Company Profile

Denali Therapeutics Inc is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease.

Get a free copy of the Zacks research report on Denali Therapeutics (DNLI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply